Hospital
Breckinridge Health, INC
Breckinridge Health, INC was paid $11.23M by Medicaid between Jan 2018 and Dec 2024, across 146 billing codes. Its largest line is 99284, emergency room visit (serious) — 10% of everything it billed.
33Billing provider infoBRECKINRIDGE HEALTH, INC
HARDINSBURG, KY 40143
HARDINSBURG, KY 40143
33aNPI1104828383assigned 06/01/2005
33bProvider typeCritical Access Hospital
28Total paid$11.23M
24GClaims309,637
24DCodes billed146
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Kentucky
Rank by total paid#11 of 16
Median peer was paid$11.73M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 42,498 | $1.44M | |
| 2019 | 47,259 | $1.34M | |
| 2020 | 45,565 | $1.43M | |
| 2021 | 57,263 | $1.65M | |
| 2022 | 47,141 | $1.78M | |
| 2023 | 41,037 | $2.03M | |
| 2024incomplete | 28,874 | $1.56M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 8,077 | 5,536 | $1.17M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 9.3% | 1,537 | 1,108 | $1.04M |
| 70450 | Computed tomography, head or brain; without contrast material | 5.0% | 1,601 | 1,083 | $562K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.8% | 6,333 | 1,285 | $544K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.6% | 3,380 | 2,259 | $522K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.5% | 798 | 519 | $504K |
| 80053 | Comprehensive metabolic panel | 4.4% | 44,234 | 22,149 | $500K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.9% | 4,208 | 3,389 | $435K |
| 80061 | Lipid panel | 2.9% | 12,914 | 9,398 | $321K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.5% | 31,459 | 19,811 | $283K |
| G0378 | Hospital observation service, per hour | 2.4% | 1,020 | 660 | $272K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.4% | 9,662 | 7,279 | $267K |
134 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.0% | 5,485 | $224K |
| 80306 | 1.9% | 4,149 | $208K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.7% | 3,896 | $195K |
| 84484 | 1.6% | 4,523 | $180K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.6% | 2,941 | $174K |
| 71045 | Radiologic examination, chest; single view | 1.5% | 3,529 | $171K |
| 71046 | Radiologic examination, chest; 2 views | 1.5% | 2,479 | $164K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.4% | 1,896 | $161K |
| 87428 | 1.3% | 3,040 | $144K | |
| 36000 | 1.3% | 3,502 | $143K | |
| 81001 | 1.3% | 7,895 | $141K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.3% | 8,404 | $141K |
| 81025 | 1.2% | 2,221 | $140K | |
| 83690 | 1.2% | 4,607 | $137K | |
| 84439 | 1.2% | 5,186 | $136K | |
| 82607 | <1% | 3,069 | $110K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,283 | $97K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,437 | $96K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,823 | $93K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 824 | $90K |
| 36415 | Collection of venous blood by venipuncture | <1% | 19,224 | $89K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,086 | $87K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,591 | $86K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,403 | $84K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,674 | $82K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 436 | $71K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,001 | $67K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 907 | $61K |
| 87070 | <1% | 1,208 | $54K | |
| 83540 | <1% | 2,102 | $53K | |
| 83605 | <1% | 1,463 | $52K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,037 | $51K |
| 83880 | <1% | 1,828 | $50K | |
| 94762 | <1% | 1,605 | $47K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 590 | $46K |
| 94664 | <1% | 1,473 | $45K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,719 | $45K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,061 | $44K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,529 | $43K |
| 82043 | <1% | 1,796 | $41K | |
| 85379 | <1% | 874 | $38K | |
| 87186 | <1% | 2,329 | $33K | |
| 82150 | <1% | 1,325 | $33K | |
| 86141 | <1% | 1,150 | $32K | |
| 84481 | <1% | 151 | $31K | |
| 80076 | <1% | 1,628 | $25K | |
| 83735 | <1% | 2,356 | $24K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 1,589 | $23K |
| 85610 | <1% | 2,927 | $21K | |
| 87077 | <1% | 4,176 | $20K | |
| 84703 | <1% | 220 | $19K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 147 | $18K |
| 73630 | <1% | 221 | $17K | |
| 87040 | <1% | 261 | $17K | |
| 85730 | <1% | 637 | $14K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 135 | $14K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 278 | $12K |
| 82553 | <1% | 291 | $12K | |
| 73610 | <1% | 162 | $12K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,341 | $11K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 70 | $11K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,560 | $11K |
| 73030 | <1% | 150 | $11K | |
| 86140 | <1% | 311 | $11K | |
| 82550 | <1% | 370 | $10K | |
| 84480 | <1% | 197 | $10K | |
| 97161 | <1% | 160 | $10K | |
| 72100 | <1% | 90 | $10K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,834 | $9K |
| 85027 | <1% | 282 | $8K | |
| 83874 | <1% | 166 | $8K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 215 | $7K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 28 | $7K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,181 | $6K |
| 82962 | <1% | 577 | $6K | |
| 73130 | <1% | 60 | $5K | |
| 82803 | <1% | 32 | $4K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 133 | $4K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 202 | $4K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 86 | $4K |
| 85652 | <1% | 209 | $4K | |
| E0440 | Stationary liquid oxygen system, purchase; includes use of reservoir, contents indicator, regulator, flowmeter, humidifier, nebulizer, cannula or mask, and tubing | <1% | 115 | $4K |
| 82746 | <1% | 92 | $4K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 908 | $3K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 42 | $3K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 170 | $3K |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 4,309 | $3K |
| 73560 | <1% | 51 | $3K | |
| 82728 | <1% | 51 | $3K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 861 | $3K |
| J2704 | Injection, propofol, 10 mg | <1% | 301 | $3K |
| 80074 | <1% | 41 | $3K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 107 | $3K |
| 84145 | <1% | 58 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 162 | $3K |
| 76536 | <1% | 13 | $2K | |
| 84436 | <1% | 28 | $2K | |
| 82948 | <1% | 414 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,365 | $2K |
| 87807 | <1% | 55 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 21 | $2K |
| 82570 | <1% | 133 | $2K | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 192 | $2K |
| 84591 | <1% | 61 | $1K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 21 | $1K |
| 73110 | <1% | 12 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 622 | $1K |
| 97164 | <1% | 23 | $1K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 63 | $1K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 26 | $1K |
| 0031A | <1% | 71 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 405 | $1K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 191 | $1K |
| 86800 | <1% | 13 | $1K | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 1,353 | $1K |
| J3490 | Unclassified drugs | <1% | 495 | $1K |
| 86308 | <1% | 27 | $939.42 | |
| 85007 | <1% | 155 | $616.55 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 309 | $395.49 |
| 90715 | <1% | 19 | $336.96 | |
| 84550 | <1% | 14 | $286.98 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 245 | $216.26 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 180 | $214.13 |
| 83550 | <1% | 40 | $201.24 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 199 | $128.35 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 23 | $120.51 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 24 | $106.43 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 32 | $100.45 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 19 | $99.33 |
| S0028 | Injection, famotidine, 20 mg | <1% | 94 | $90.48 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 72 | $90.03 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 38 | $84.96 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 30 | $47.76 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 16 | $16.08 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPORTMAN, ANGELA (CEO)
| Provider | Location | Paid |
|---|---|---|
| Breckinridge Health INC | Hardinsburg, KY | $665K |
| Breckinridge Health INC | Hardinsburg, KY | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.